Literature DB >> 8803806

Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis.

T Joseph-Horne1, R S Loeffler, D W Hollomon, S L Kelly.   

Abstract

Amphotericin B resistant mutants of Cryptococcus neoformans were isolated accumulating mainly ergosterol. Cross-resistance to azole antifungals was not observed. Together with previous data this indicates that at least three categories of amphotericin B resistance can arise: sterol mutants, amphotericin B and azole cross-resistant mutants and amphotericin B resistant mutants with no azole cross-resistance.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8803806

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN： 0268-1218


  9 in total

1.  Cell Wall Changes in Amphotericin B-Resistant Strains from Candida tropicalis and Relationship with the Immune Responses Elicited by the Host.

Authors:  Ana C Mesa-Arango; Cristina Rueda; Elvira Román; Jessica Quintin; María C Terrón; Daniel Luque; Mihai G Netea; Jesus Pla; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.

Authors:  Ana Cecilia Mesa-Arango; Nuria Trevijano-Contador; Elvira Román; Ruth Sánchez-Fresneda; Celia Casas; Enrique Herrero; Juan Carlos Argüelles; Jesús Pla; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 3.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

4.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

5.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 6.  Plasma membrane lipids and their role in fungal virulence.

Authors:  Antonella Rella; Amir M Farnoud; Maurizio Del Poeta
Journal:  Prog Lipid Res       Date:  2015-12-15       Impact factor: 16.195

7.  Erg6 affects membrane composition and virulence of the human fungal pathogen Cryptococcus neoformans.

Authors:  Fabiana Freire M Oliveira; Hugo Costa Paes; Luísa Defranco F Peconick; Fernanda L Fonseca; Clara Luna Freitas Marina; Anamélia Lorenzetti Bocca; Mauricio Homem-de-Mello; Márcio Lourenço Rodrigues; Patrícia Albuquerque; André Moraes Nicola; J Andrew Alspaugh; Maria Sueli S Felipe; Larissa Fernandes
Journal:  Fungal Genet Biol       Date:  2020-03-19       Impact factor: 3.495

8.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.

Authors:  Ana C Mesa-Arango; Liliana Scorzoni; Oscar Zaragoza
Journal:  Front Microbiol       Date:  2012-08-08       Impact factor: 5.640

Review 9.  Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance.

Authors:  Hans Carolus; Siebe Pierson; Katrien Lagrou; Patrick Van Dijck
Journal:  J Fungi (Basel)       Date:  2020-11-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.